Valuing Innovations - Opportunities and Challenges to Better Define and Measure Innovative Properties of Health Technologies

Speaker(s)

Discussion Leader: Richard Xie, PhD, The Innovation and Value Initiative, Newton, MA, USA
Discussants: Jon Campbell, PhD, Institute for Clinical and Economic Review, Hingham, MA, USA; Joshua Krieger, PhD, Entrepreneurial Management Unit, Harvard Business School, Newton, MA, USA; Maia Z. Laing, MBA, Optum, Washington, DC, USA

PURPOSE:

  • Discuss the strengths and weaknesses in accounting for innovations in existing approaches of health technology assessments (HTA),
  • Identify prioritized areas for methods and data research to better define and measure innovations,
  • Outline practical steps that different stakeholders can take to advance the methods and practice to better account for innovations in HTA.

DESCRIPTION:

Over the past decades, innovations in health technologies have been a major contributor to improved life expectancy and quality of life. However, as biomedical and digital innovations accelerate, the methods and practice to define and measure innovations in HTA are not keeping pace.

IVI convened a multi-stakeholder expert roundtable to identify prioritized areas that need further research in methods and data to better define and measure innovations. This workshop brings together cross-stakeholder participants to highlight these prioritized areas, and outline action steps that stakeholders can take to better account for innovations in HTA.

In this workshop, Dr. Xie will first discuss the importance of considering innovations in HTA, and briefly introduce the Expert Roundtable held by IVI to identify prioritized areas for research. (8 minutes)

Ms. Laing will provide an overview of how innovative properties of health technologies are being considered in current approaches to HTA, and discuss their strengths and limitations. (8 minutes)

Based on the results from the roundtable held by IVI and live-polling with the audience, Dr. Campbell will discuss prioritized areas for additional research, and how novel methods and data can be better integrated into existing HTA frameworks. (8 minutes)

Dr. Krieger will discuss the steps that stakeholders can take to better account for innovations in HTA, and the likely impacts on patients’ well-being and long-term dynamic efficiency. (8 minutes)

The workshop will end with a facilitated dialogue and live Q&A with the audience.

Code

251

Topic

Health Technology Assessment